Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34 Filing Table of Contents
Document/ExhibitDescriptionPagesSize
1: 10-K Annual Report HTML 1.45M
2: EX-10.25 Material Contract HTML 35K
3: EX-10.40 Material Contract HTML 63K
4: EX-10.42 Material Contract HTML 206K
5: EX-23.1 Consent of Experts or Counsel HTML 29K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 35K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 35K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 32K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 32K
70: R1 Document and Entity Information HTML 59K
56: R2 Consolidated Balance Sheets HTML 140K
68: R3 Consolidated Balance Sheets (Parenthetical) HTML 63K
73: R4 Consolidated Statement of Operations and HTML 109K
Comprehensive Loss
92: R5 Consolidated Statements of Changes in Convertible HTML 256K
Preferred Stock and of Stockholders’ Equity
(Deficit)
59: R6 Consolidated Statements of Changes in Convertible HTML 41K
Preferred Stock and of Stockholders’ Equity
(Deficit) (Parenthetical)
67: R7 Consolidated Statements of Cash Flows HTML 234K
51: R8 The Company and Basis of Presentation HTML 44K
41: R9 Summary of Significant Accounting Policies HTML 83K
93: R10 License Agreements HTML 37K
75: R11 Medicis Settlement HTML 43K
74: R12 Fair Value Measurements HTML 123K
80: R13 Balance Sheet Components HTML 82K
81: R14 Notes Payable HTML 60K
78: R15 Convertible Notes, Warrants, and Related HTML 61K
Derivatives
82: R16 Interest Expense HTML 62K
69: R17 Commitments and Contingencies HTML 47K
71: R18 Common Stock HTML 51K
77: R19 Convertible Preferred Stock HTML 62K
101: R20 Warrants HTML 64K
88: R21 Stock Option Plan HTML 232K
63: R22 Net Income (Loss) per Share Attributable to Common HTML 80K
Stockholders
76: R23 Income Taxes HTML 93K
65: R24 Defined Contribution Plan HTML 34K
32: R25 Subsequent Events HTML 37K
89: R26 Quarterly Results of Operations (Unaudited) HTML 86K
97: R27 Summary of Significant Accounting Policies HTML 147K
(Policies)
46: R28 Fair Value Measurements (Tables) HTML 117K
45: R29 Balance Sheet Components (Tables) HTML 85K
49: R30 Notes Payable (Tables) HTML 42K
50: R31 Convertible Notes, Warrants, and Related HTML 41K
Derivatives (Tables)
52: R32 Interest Expense (Tables) HTML 60K
24: R33 Commitments and Contingencies (Tables) HTML 37K
86: R34 Common Stock (Tables) HTML 48K
61: R35 Convertible Preferred Stock (Tables) HTML 52K
64: R36 Warrants (Tables) HTML 52K
36: R37 Stock Option Plan (Tables) HTML 210K
100: R38 Net Income (Loss) per Share Attributable to Common HTML 81K
Stockholders (Tables)
16: R39 Income Taxes (Tables) HTML 83K
53: R40 Quarterly Results of Operations (Unaudited) HTML 85K
(Tables)
91: R41 The Company and Basis of Presentation - Additional HTML 90K
Information (Detail)
34: R42 Summary of Significant Accounting Policies HTML 71K
(Details)
44: R43 License Agreements (Details) HTML 52K
48: R44 Medicis Settlement - Additional Information HTML 79K
(Detail)
57: R45 Fair Value Measurements - Schedule of Fair Value HTML 89K
of Financial Instruments (Detail)
23: R46 Fair Value Measurements - Summary of Changes in HTML 95K
Fair Value of Financial Instruments (Detail)
40: R47 Fair Value Measurements (Narrative) (Details) HTML 31K
18: R48 Balance Sheet Components - Additional Information HTML 38K
(Detail)
90: R49 Balance Sheet Components - Schedule of Property HTML 55K
and Equipment, Net (Detail)
33: R50 Balance Sheet Components - Schedule of Prepaid HTML 42K
Expenses and Other Current Assets (Detail)
87: R51 Balance Sheet Components - Schedule of Accruals HTML 57K
and Other Current Liabilities (Detail)
37: R52 Balance Sheet Components - Schedule of Other HTML 40K
Non-Current Assets (Detail)
54: R53 Notes Payable - Hercules Notes Payable (Detail) HTML 97K
17: R54 Notes Payable - Essex Capital Notes (Detail) HTML 111K
21: R55 Notes Payable - Summary of Aggregate Total Future HTML 37K
Minimum Lease Payments under the Financing
Obligation (Detail)
47: R56 Notes Payable - Summary of Future Principal HTML 44K
Payments under the Notes Payable (Detail)
27: R57 Convertible Notes, Warrants, and Related HTML 154K
Derivatives - Additional Information (Detail)
94: R58 Convertible Notes, Warrants, and Related HTML 46K
Derivatives - Fair Value Assumptions Using "Monte
Carle" Simulation (Details)
60: R59 Interest Expense - Summary of Interest Expense by HTML 56K
Cash and Non-Cash Components (Detail)
79: R60 Commitments and Contingencies - Additional HTML 44K
Information (Detail)
39: R61 Commitments and Contingencies - Schedule of Future HTML 48K
Minimum Lease Payments under Non-Cancelable
Operating Leases (Detail)
42: R62 Common Stock - Additional Information (Detail) HTML 61K
85: R63 Convertible Preferred Stock - Additional HTML 137K
Information (Detail)
83: R64 Convertible Preferred Stock - Outstanding HTML 80K
(Details)
62: R65 Warrants - Additional Information (Detail) HTML 151K
84: R66 Warrants - Schedule of Warrants (Details) HTML 55K
38: R67 Warrants - Assumptions Using Black-Scholes Model HTML 39K
(Details)
66: R68 Stock Option Plan - Additional Information HTML 140K
(Detail)
96: R69 Stock Option Plan - Summary of Stock Option and HTML 175K
Restricted Stock Award Activity (Details)
20: R70 Stock Option Plan - Stock Options Outstanding and HTML 89K
Exercisable (Details)
31: R71 Stock Option Plan - Summary of Restricted Stock HTML 64K
Award Activity (Details)
55: R72 Stock Option Plan - Fair Value Assumptions HTML 59K
(Details)
26: R73 Stock Option Plan - Schedule of Stock-based HTML 41K
Compensation Expense (Details)
99: R74 Net Income (Loss) per Share Attributable to Common HTML 104K
Stockholders - Schedule of Computation of Basic
and Diluted Net Income (Loss) Per Share
Attributable to Common Stockholders (Detail)
35: R75 Net Income (Loss) per Share Attributable to Common HTML 50K
Stockholders - Summary of Common Stock Equivalents
Excluded from Computation of Diluted Net Income
(Loss) Per Share (Detail)
28: R76 Income Taxes - Additional Information (Detail) HTML 61K
30: R77 Income Taxes - Deferred Tax Assets and Liabilities HTML 61K
(Details)
22: R78 Income Taxes - Effective Tax Rate Reconciliation HTML 58K
(Details)
25: R79 Income Taxes - Unrecognized Tax Benefits (Details) HTML 40K
72: R80 Defined Contribution Plan - Additional Information HTML 31K
(Details)
29: R81 Subsequent Events - Additional Information HTML 82K
(Details)
95: R82 Quarterly Results of Operations (Unaudited) - HTML 67K
Additional Information (Details)
98: XML IDEA XML File -- Filing Summary XML 166K
19: EXCEL IDEA Workbook of Financial Reports XLSX 270K
43: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 2.07M
10: EX-101.INS XBRL Instance -- rvnc-20141231 XML 3.11M
12: EX-101.CAL XBRL Calculations -- rvnc-20141231_cal XML 254K
13: EX-101.DEF XBRL Definitions -- rvnc-20141231_def XML 895K
14: EX-101.LAB XBRL Labels -- rvnc-20141231_lab XML 2.31M
15: EX-101.PRE XBRL Presentations -- rvnc-20141231_pre XML 1.37M
11: EX-101.SCH XBRL Schema -- rvnc-20141231 XSD 250K
58: ZIP XBRL Zipped Folder -- 0001628280-15-001461-xbrl Zip 322K
1. I have reviewed this annual report on Form 10-K of Revance Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the
registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control
over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process,
summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
